i luv me some chemo

@MattDun17 Dude…. OUCH!!!!! 🌹🏴󠁧󠁢󠁥󠁮󠁧󠁿

@wallabies @StanSportAU Go @wallabies love from #Dudley #NSW!!

Your 23 to face Los Pumas in Santa Fe 🦘 🗓️ Sunday 8th September | 5:00am AEST 🏟️ Santa Fe 📺 @stansportau #Wallabies #TRC2024

@TommyJohn00 Totally agree with the statements above. The increasing incidence of patients with cancer and the increasing complexity of care demand an in place highly trained workforce but current budgetary constraints require us to “do more with less”. There needs to be investment in med onc

1/5 MOGA chair warns over looming workforce shortages: thelimbic.com/oncology/moga-… In hospitals as expectations grow in the community for cancer care and our patients are living longer, we are experiencing higher workloads amongst both junior and senior staff.

@DrCraigGedye @CancerAustralia @CEOCancerAus The bow tie will come out when I become chair… be afraid!!!

@CancerAustralia @CEOCancerAus Congratulations and thanks for your leadership Dorothy! @drjameslynam where is your bow-tie?

Congratulations to @CEOCancerAus Prof Dorothy Keefe, recipient of the 2024 Professor M. Tattersall Heroes Award! Presented at the 2024 MOGA ASM, this Award recognises contributions by medical oncologists that honour the spirit and commitment of the late Prof Martin Tattersall AO.

@DKarikios @MOGA_ORG @oncology_bg Not the best angle….

Awkward photo with the band as a mandatory part of @MOGA_ORG ASM #MOGA24 @oncology_bg

Job Opportunity: Calvary Mater Newcastle seeks Medical Oncology Advanced Trainee. Fixed term full-time. Closes 21 July. moga.org.au/oncology-posit…

@MattDun17 @TheASMR1 @RUNDIPG Well deserved!!!

Thank you @TheASMR1 This is an incredible honour and a tremendous platform to advocate for Australian Health and Medical Research. I will try to do our constituents and our community proud. #DunLab @RUNDIPG

@DrLizConnolly @DrBenTran @OingC1 @onconess @WeickhardtOnc @vincenzi_b @COBLH @_rarecancer @RareCancers @MOGA_ORG @ANZUPtrials @PeterMacCC @CMRI_AUS Well done Liz and team. An important paper!!!!

High dose #chemo +stem cell transplant for first or subsequent #salvage in #relapsed germ cell tumours Proud to contribute to international study of n=283 #AYA relapsed #GCT from 11 centres w @DrBenTran @OingC1 @onconess @WeickhardtOnc @vincenzi_b Link: authors.elsevier.com/sd/article/S20…

@mhong_88 @MarkHughesFdn @MOGA_ORG As you so eloquently state, the QOL benefits of specialised nursing support/care coordinators is well established. This is the first paper to demonstrate that with this QOL improvement comes health service savings that make investment in these clinicians cost effective!!!

Our work on CCC, who provide excellent support to patients, carers and clinicians, but are also cost effective for health services. Many CCC are philanthropically funded, thank you @MarkHughesFdn, but time to review funding model? @drjameslynam @MOGA_ORG academic.oup.com/nop/article/do…

@navstruck @KfOncology Very interested in imVIGOR especially considering the much more significant recurrence rate in this disease than seen in the DYNAMIC and considering the ongoing debate of adjuvant IO in this population…

@KfOncology ctDNA is ready in certain contexts for prime time - to be integrated into the treatment paradigm. I’m most interested in its role in identifying those who would benefit most from adjuvant therapy - imVIGOR (bladder) and dynamic Rectal @drjameslynam

So excited to have @pashtoonkasi discuss #ctDNA and the role of #liquidbiopsy in #precisiononcology #oncology #PrecisionMedicine #virtualmolecularounds #vmr Presented on behalf of the Precision Oncology Experimental Therapeutics program @ACTION_UCalgary @UCalgaryMed @ucalgary

@mhong_88 @jenhelenmar Great talk indeed. The high proportion of patients that think there is good evidence for an anti cancer effect of cannabis is a scary statistic!

Interesting talk on patients' views on cannabis from Dr Joe Taylor #MOGA22 @drjameslynam @jenhelenmar

Join our #MedicalOncology team in Newcastle as a #ClinicalTrial Fellow. One of NSW busiest clinical research teams, gain wide experience and see many opportunities. Immediate start, FT or PT, and multi-year possible. calvarycareers.mercury.com.au/ViewPosition.a… Credit: Ian Nord

@navstruck @mhong_88 @DrCraigGedye I wouldn’t push too hard. We want people fit enough for their cystectomy…

@mhong_88 @DrCraigGedye @drjameslynam Similar numbers of patients got to cystectomy. Of course fit trial patients may not translate to our heterogenous real world population. Will you stop at 4? Or push on?

ddMVAC as expected is the better approach in the perioperative setting for MIBC #esmo21 #bladdercancer @DrCraigGedye @drjameslynam

@mhong_88 @DrCraigGedye Now what to do with the cN+ patients??? Understand why this cohort was excluded from this study but annoys me that this is an exclusion factor for all the currently recruiting neoadjuvant chemo+IO studies!

@mhong_88 @DrCraigGedye It’s a shame they designed the trial with 6 cycles ddMVAC. One of the great benefits of this protocol is getting to surgery quickly after 3 or 4 cycles. The fact that only 60% completed all 6 cycles fits with my experience of toxicity. I’ll still be using aMVAC

Medical Oncologist roles at #CalvaryMaterNewcastle. Join our busy academic service. Two Permanent Part-time Positions (0.5 FTE/20 hours per week) calvarycareers.mercury.com.au/ViewPosition.a… Please share.

A big welcome to the 20 new ESMO Designated Centres of Integrated #Oncology & #PalliativeCare 🔗ow.ly/lWMX50G25SU @MOU_Brno @adrziekenhuis @HBCHRCVIZAG @MLauraVillal @SaludMadrid @BurjeelMediCity @alshamsi2000 @CalvaryCareAUS @drjameslynam @ICM_Montpellier @ASLCittaTorino

@navstruck @DrCraigGedye @mhong_88 @oncology_bg @Roche Doesn’t seem to hold true in the urothelial IO space where the “confirmatory” trials have in no significant way confirmed the accelerated approval….

@DrCraigGedye @mhong_88 @oncology_bg In fairness to @Roche they’re sticking to the bargain- to keep approval they’d have to do another large trial. Their initial trial failed, a subgroup was provocative then the whole devpt programme crumbled on impassion131.this is why we have rigorous stat plans and a regulator

Excellent use of the #fda accelerated approval system and kudos to @Roche for voluntarily withdrawing Atezolizumab in mTNBC given the update SoC of pembro in CPS>10 with +veOS due at #esmo21 @OncoAlert #immunotherapy #bcsm @Merck

@DKarikios @MOGA_ORG @drprunellab Long time coming and richly deserved!!

Very humbled to be given the responsibility of @MOGA_ORG chair today. Hope I can make those that have trusted me with the role proud. Big shoes to fill after @drprunellab I do my best to advocate for our patients and our profession.

@DrChoueiri M1 NED 😳😳. Small numbers but still!

8/ Pembrolizumab significantly improved DFS as compared to placebo (HR=0.68 ; 95%CI: 0.53-0.87 ; p=0.002, 2-sided), with benefits identified across most key subgroups (all HR<1). DFS rates at 2 years were 77.3 and 68.1% in the pembrolizumab and placebo groups, respectively.

1/ On the heels of @ASCO #ASCO21 plenary, we are happy to share the results of KEYNOTE-564 trial of adjuvant pembrolizumab in mRCC just published in @NEJM ! A step towards better outcomes for all our patients with kidney cancer! nejm.org/doi/full/10.10… @OncoAlert @tompowles1